CONTEXT: Tics in Tourette syndrome begin in childhood, peak in early adolescence, and often decrease by early adulthood. However, some adult patients continue to have impairing tics. Medications for tics are often effective but can cause adverse effects. Behavior therapy may offer an alternative but has not been examined in a large-scale controlled trial in adults. OBJECTIVE: To test the efficacy of a comprehensive behavioral intervention for tics in adults with Tourette syndrome of at least moderate severity. DESIGN: A randomized controlled trial with posttreatment evaluations at 3 and 6 months for positive responders. SETTING: Three outpatient research clinics. PATIENTS: Patients (N = 122; 78 males; age range, 16-69 years) with Tourette syndrome or chronic tic disorder were recruited between December 27, 2005, and May 21, 2009. INTERVENTIONS: Patients received 8 sessions of comprehensive behavioral intervention for tics or 8 sessions of supportive treatment for 10 weeks. Patients with a positive response were given 3 monthly booster sessions. MAIN OUTCOME MEASURES: Total tic score on the Yale Global Tic Severity Scale and the Clinical Global Impression-Improvement scale rated by a clinician masked to treatment assignment. RESULTS:Behavior therapy was associated with a significantly greater mean (SD) decrease on the Yale Global Tic Severity Scale (24.0 [6.47] to 17.8 [7.32]) from baseline to end point compared with the control treatment (21.8 [6.59] to 19.3 [7.40]) (P < .001; effect size = 0.57). Twenty-four of 63 patients (38.1%) were rated as much improved or very much improved on the Clinical Global Impression-Improvement scale compared with 4 of 63 (6.4%) in the control group (P < .001). Attrition was 13.9%, with no difference across groups. Patients receiving behavior therapy who were available for assessment at 6 months after treatment showed continued benefit. CONCLUSION:Comprehensive behavior therapy is a safe and effective intervention for adults with Tourette syndrome. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00231985.
RCT Entities:
CONTEXT: Tics in Tourette syndrome begin in childhood, peak in early adolescence, and often decrease by early adulthood. However, some adult patients continue to have impairing tics. Medications for tics are often effective but can cause adverse effects. Behavior therapy may offer an alternative but has not been examined in a large-scale controlled trial in adults. OBJECTIVE: To test the efficacy of a comprehensive behavioral intervention for tics in adults with Tourette syndrome of at least moderate severity. DESIGN: A randomized controlled trial with posttreatment evaluations at 3 and 6 months for positive responders. SETTING: Three outpatient research clinics. PATIENTS: Patients (N = 122; 78 males; age range, 16-69 years) with Tourette syndrome or chronic tic disorder were recruited between December 27, 2005, and May 21, 2009. INTERVENTIONS:Patients received 8 sessions of comprehensive behavioral intervention for tics or 8 sessions of supportive treatment for 10 weeks. Patients with a positive response were given 3 monthly booster sessions. MAIN OUTCOME MEASURES: Total tic score on the Yale Global Tic Severity Scale and the Clinical Global Impression-Improvement scale rated by a clinician masked to treatment assignment. RESULTS: Behavior therapy was associated with a significantly greater mean (SD) decrease on the Yale Global Tic Severity Scale (24.0 [6.47] to 17.8 [7.32]) from baseline to end point compared with the control treatment (21.8 [6.59] to 19.3 [7.40]) (P < .001; effect size = 0.57). Twenty-four of 63 patients (38.1%) were rated as much improved or very much improved on the Clinical Global Impression-Improvement scale compared with 4 of 63 (6.4%) in the control group (P < .001). Attrition was 13.9%, with no difference across groups. Patients receiving behavior therapy who were available for assessment at 6 months after treatment showed continued benefit. CONCLUSION: Comprehensive behavior therapy is a safe and effective intervention for adults with Tourette syndrome. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00231985.
Authors: Sabine Wilhelm; Thilo Deckersbach; Barbara J Coffey; Antje Bohne; Alan L Peterson; Lee Baer Journal: Am J Psychiatry Date: 2003-06 Impact factor: 18.112
Authors: F R Sallee; R Kurlan; C G Goetz; H Singer; L Scahill; G Law; V M Dittman; P B Chappell Journal: J Am Acad Child Adolesc Psychiatry Date: 2000-03 Impact factor: 8.829
Authors: Clare M Eddy; Andrea E Cavanna; Mariangela Gulisano; Antonella Agodi; Martina Barchitta; Paola Calì; Mary M Robertson; Renata Rizzo Journal: Mov Disord Date: 2010-11-10 Impact factor: 10.338
Authors: J F Leckman; M A Riddle; M T Hardin; S I Ort; K L Swartz; J Stevenson; D J Cohen Journal: J Am Acad Child Adolesc Psychiatry Date: 1989-07 Impact factor: 8.829
Authors: Sangchoon Jeon; John T Walkup; Douglas W Woods; Alan Peterson; John Piacentini; Sabine Wilhelm; Lily Katsovich; Joseph F McGuire; James Dziura; Lawrence Scahill Journal: Contemp Clin Trials Date: 2013-08-31 Impact factor: 2.226
Authors: Joseph F McGuire; Epiphanie Nyirabahizi; Katharina Kircanski; John Piacentini; Alan L Peterson; Douglas W Woods; Sabine Wilhelm; John T Walkup; Lawrence Scahill Journal: Psychiatry Res Date: 2013-09-27 Impact factor: 3.222
Authors: H Ben-Pazi; P Browne; P Chan; E Cubo; M Guttman; A Hassan; J Hatcher-Martin; Z Mari; E Moukheiber; N U Okubadejo; A Shalash Journal: Curr Neurol Neurosci Rep Date: 2018-04-13 Impact factor: 5.081
Authors: Joseph F McGuire; John Piacentini; Eric A Storch; Tanya K Murphy; Emily J Ricketts; Douglas W Woods; John W Walkup; Alan L Peterson; Sabine Wilhelm; Adam B Lewin; James T McCracken; James F Leckman; Lawrence Scahill Journal: Neurology Date: 2018-04-13 Impact factor: 9.910
Authors: Emily J Ricketts; Joseph F McGuire; Susanna Chang; Deepika Bose; Madeline M Rasch; Douglas W Woods; Matthew W Specht; John T Walkup; Lawrence Scahill; Sabine Wilhelm; Alan L Peterson; John Piacentini Journal: Behav Ther Date: 2017-05-25
Authors: Kevin J Black; Joseph Jankovic; Tamara Hershey; Kevin St P McNaught; Jonathan W Mink; John Walkup Journal: J Obsessive Compuls Relat Disord Date: 2014-10-01 Impact factor: 1.677
Authors: Hilary Weingarden; Lawrence Scahill; Susanne Hoeppner; Alan L Peterson; Douglas W Woods; John T Walkup; John Piacentini; Sabine Wilhelm Journal: Compr Psychiatry Date: 2018-04-23 Impact factor: 3.735
Authors: Mariela Rance; Christopher Walsh; Denis G Sukhodolsky; Brian Pittman; Maolin Qiu; Stephen A Kichuk; Suzanne Wasylink; William N Koller; Michael Bloch; Patricia Gruner; Dustin Scheinost; Christopher Pittenger; Michelle Hampson Journal: Neuroimage Date: 2018-05-02 Impact factor: 6.556